e-Drug3D

1574

ICOSAPENT


INN
ICOSAPENT

(is an active metabolite)

cas 10417-94-4
CLASS

CARDIOVASCULAR
ADJUNCT TO DIET TO REDUCE TRIGLYCERIDE (TG) LEVELS IN ADULT PATIENTS WITH SEVERE (>= 500 MG/DL) HYPERTRIGLYCERIDEMIA
POTENTIAL MECHANISMS OF ACTION INCLUDE INCREASED BETA-OXIDATION
INHIBITION OF ACYL-COA:1,2-DIACYLGLYCEROL ACYLTRANSFERASE (DGAT)
DECREASED LIPOGENESIS IN THE LIVER
AND INCREASED PLASMA LIPOPROTEIN LIPASE ACTIVITY

ROUTE (list)

-

NATURAL MOLECULE (link)

ATC code

PK parameters

VD 88 LITER
Cl 0.68 LITER / HOUR
PPB 99 PERCENT
t1/2 89 HOUR

Target

-

PDB
1IGX (CRYSTAL STRUCTURE OF EICOSAPENTANOIC ACID BOUND IN THE CYCLOOXYGENASE CHANNEL OF PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE-1.)

Ligand code = EPA (link to the list of PDB complexes)

Download experimental 3D coordinates of EPA with added hydrogens

DrugCentral

Unknown

Download SDF file 5,8,11,14,17-Eicosapentaenoic acid, (5Z,8Z,11Z,14Z,17Z)-

Formula:
C20H30O2

Calculated chemical properties:

MW 301.43
NB_atoms 22
XLogP 4.66
PSA 35.771
NB_HD 0
NB_HA 2
fsp3 0.45
Lipinski(0=no;1=yes) 1

FDA
-

Other links:

PubChem
ChemicalProbes

U.S. repository of Clinical Trials

VigiAccess
SIDER side effects

ChemSynthesis
Patent@SureChEMBL